stella
beta
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy — Stella
Recruiting
Back to Nasopharyngeal Cancinoma (NPC) trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(2 sites)
China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian
View full record on ClinicalTrials.gov